Free Access
Issue
Med Sci (Paris)
Volume 28, Number 10, Octobre 2012
Page(s) 852 - 857
Section Récepteurs couplés aux protéines G
DOI https://doi.org/10.1051/medsci/20122810013
Published online 12 October 2012
  1. Lagerström MC, Schiöth HB. Structural diversity of G protein-coupled receptors and significance for drug discovery. Nat Rev Drug Discov 2008 ; 7 : 339–357. [CrossRef] [PubMed] [Google Scholar]
  2. Imming P, Sinning C, Meyer A. Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov 2006 ; 5 : 821–834. [CrossRef] [PubMed] [Google Scholar]
  3. Kenakin T, Miller LJ. Seven transmembrane receptors as shapeshifting proteins: The impact of allosteric modulation and functional selectivity on new drug discovery. Pharmacol Rev 2010 ; 62 : 265–304. [CrossRef] [PubMed] [Google Scholar]
  4. De Amici M, Dallanoce C, Holzgrabe U, et al. Allosteric ligands for G protein-coupled receptors: A novel strategy with attractive therapeutic opportunities. Med Res Rev 2010 ; 30 : 463–549. [PubMed] [Google Scholar]
  5. Monod JJ, Wyman J, Changeux JP. On the nature of allosteric transition: a plausible model. J Mol Biol 1965 ; 12 : 88–118. [CrossRef] [PubMed] [Google Scholar]
  6. Hall DA. Modeling the functional effects of allosteric modulators at pharmacological receptors: Extension of the two-state model of receptor activation. Mol Pharmacol 2000 ; 58 : 1412–1423. [PubMed] [Google Scholar]
  7. Costa T, Cotecchia S. Historical review: Negative efficacy and the constitutive activity of G-protein-coupled receptors. Trends Pharmacol Sci 2005 ; 26 : 618–624. [CrossRef] [PubMed] [Google Scholar]
  8. Lecat S, Bucher B, Mely Y, Galzi JL. Mutations in the extracellular amino-terminal domain of the NK2 neurokinin receptor abolish cAMP signaling but preserve intracellular calcium responses. J Biol Chem 2002 ; 277 : 42034–42048. [CrossRef] [PubMed] [Google Scholar]
  9. Stallaert W, Dorn JF, van der Westhuizen E, et al. Impedance responses reveal beta2-adrenergic receptor signaling pluridimensionality and allow classification of ligands with distinct signaling profiles. PLoS One 2012 ; 7 : 1–14. [CrossRef] [PubMed] [Google Scholar]
  10. Congreve M, Langmead CJ, Mason JS, Marshall FH. Progress in structure based drug design for G protein-coupled receptors. J Med Chem 2011 ; 54 : 4283–4311. [CrossRef] [PubMed] [Google Scholar]
  11. Bokoch MP, Zou Y, Rasmussen SGF, et al. Ligand-specific regulation of the extracellular surface of a G-protein-coupled receptor. Nature 2010 ; 463 : 108–114. [CrossRef] [PubMed] [Google Scholar]
  12. Ilien B, Glasser N, Clamme JP, et al. Pirenzepine promotes the dimerization of muscarinic M1 receptors through a three-step binding process. J Biol Chem 2009 ; 284 : 19533–19543. [CrossRef] [PubMed] [Google Scholar]
  13. Ilien B, Franchet C, Bernard P, et al. Fluorescence resonance energy transfer to probe human M1 muscarinic receptor structure and drug binding properties. J Neurochem 2003 ; 85 : 768–778. [CrossRef] [PubMed] [Google Scholar]
  14. Vollmer JY, Alix P, Chollet A, et al. Subcellular compartmentalization of activation and desensitization of responses mediated by NK2 neurokinin receptors. J Biol Chem 1999 ; 274 : 37915–37922. [CrossRef] [PubMed] [Google Scholar]
  15. Maillet EL, Pellegrini N, Valant C, et al. A novel, conformation-specific allosteric inhibitor of the tachykinin NK2 receptor (NK2R) with functionally selective properties. FASEB J 2007 ; 21 : 2124–2134. [CrossRef] [PubMed] [Google Scholar]
  16. Palanche T, Ilien B, Zoffmann S, et al. The neurokinin A receptor activates calcium and cAMP responses through distinct conformational states. J Biol Chem 2001 ; 276 : 34853–34861. [CrossRef] [PubMed] [Google Scholar]
  17. Sprang S. GEFs: master regulators of G-protein activation. Trends Biochem Sci 2001 ; 26 : 266–267. [CrossRef] [PubMed] [Google Scholar]
  18. Strange PG. Agonist binding to G-protein coupled receptors. Br J Pharmacol 2000 ; 129 : 820–821. [CrossRef] [PubMed] [Google Scholar]
  19. Swaminath G, Steenhuis J, Kobilka B, Lee TW. Allosteric modulation of beta2-adrenergic receptor by Zn2+. Mol Pharmacol 2002 ; 61 : 65–72. [CrossRef] [PubMed] [Google Scholar]
  20. Paila YD, Chattopadhyay A. The function of G-protein coupled receptors and membrane cholesterol: specific or general interaction ? Glycoconj J 2009 ; 26 : 711–720. [CrossRef] [PubMed] [Google Scholar]
  21. Bockaert J, Fagni L, Dumuis A, Marin P. GPCR interacting proteins (GIP). Pharm Ther 2004 ; 103 : 203–221. [CrossRef] [PubMed] [Google Scholar]
  22. Janz JM, Ren Y, Looby R, et al. Direct interaction between an allosteric agonist pepducin and the chemokine receptor CXCR4. J Am Chem Soc 2011 ; 133 : 15878–15881. [CrossRef] [PubMed] [Google Scholar]
  23. Birdsall NJM, Lazareno S. Allosterism at muscarinic receptors: Ligands and mechanisms. Mini-Rev Med Chem 2005 ; 33 : 523–543. [CrossRef] [Google Scholar]
  24. Digby GJ, Shirey JK, Conn PJ. Allosteric activators of muscarinic receptors as novel approaches for treatment of CNS disorders. Mol Biosyst 2010 ; 6 : 1345–1354. [CrossRef] [PubMed] [Google Scholar]
  25. Mohr K, Tränkle C, Kostenis E, et al. Rational design of dualsteric GPCR ligands: quests and promise. Br J Pharmacol 2010 ; 159 : 997–1008. [CrossRef] [PubMed] [Google Scholar]
  26. Tahtaoui C, Parrot I, Klotz P, et al. Fluorescent pirenzepine derivatives as potential bitopic ligands of the human M1 muscarinic receptor. J Med Chem 2004 ; 47 : 4300–4315. [CrossRef] [PubMed] [Google Scholar]
  27. Valant C, Maillet E, Bourguignon JJ, et al. Allosteric functional switch of neurokinin A-mediated signaling at the neurokinin NK2 receptor: structural exploration. J Med Chem 2009 ; 52 : 5999–6011. [CrossRef] [PubMed] [Google Scholar]
  28. Urwyler S. Allosteric modulation of Family C G-protein-coupled receptors : From molecular insights to therapeutic perspectives. Pharmacol Rev 2011 ; 63 : 59–126. [CrossRef] [PubMed] [Google Scholar]
  29. Goudet C, Gaven F, Kniazeff J, et al. Heptahelical domain of metabotropic glutamate receptor 5 behaves like rhodopsin-like receptors. Proc Natl Acad Sci USA 2004 ; 101 : 378–383. [CrossRef] [PubMed] [Google Scholar]
  30. Schann S, Mayer S, Franchet C, et al. Chemical switch of a metabotropic glutamate receptor 2 silent allosteric modulator into dual metabotropic glutamate receptor 2/3 negative/positive allosteric modulators. J Med Chem 2010 ; 53 : 8775–8779. [CrossRef] [PubMed] [Google Scholar]
  31. Sebag JA, Pantel J. Ciblage thérapeutique des récepteurs couplés aux protéines G : la voie allostérique. Med Sci (Paris) 2012 ; 28 : 845–851. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  32. Lebon G, Tate C. Les récepteurs couplés aux protéines G dans la lumière. Med Sci (Paris) 2012 ; 28 : 876–882. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  33. Banères JL, Mouillac B. Manipulation des RCPG : expression, purification et stabilisation in vitro. Med Sci (Paris) 2012 ; 28 : 837–844. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  34. Jockers R, Gbahou F, Tadagaki K, Kamal M. Oligomérisation des protéines humaines et virales à sept domaines transmembranaires : nouvelle stratégie virale pour manipuler la cellule hôte. Med Sci (Paris) 2012 ; 28 : 864–869. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  35. Haga K, Kruse AC, Asada H, et al. Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist. Nature 2012 ; 482 : 547–551. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.